Molecular Interaction Fingerprints

[1]  Didier Rognan,et al.  Encoding Protein-Ligand Interaction Patterns in Fingerprints and Graphs , 2013, J. Chem. Inf. Model..

[2]  Kam Y. J. Zhang,et al.  Pharmacophore modelling as a virtual screening tool for the discovery of small molecule protein-protein interaction inhibitors. , 2012, Current pharmaceutical design.

[3]  M. Gilson,et al.  Public domain databases for medicinal chemistry. , 2012, Journal of medicinal chemistry.

[4]  H. Gohlke,et al.  Structure-based computational analysis of protein binding sites for function and druggability prediction. , 2012, Journal of biotechnology.

[5]  Rama Kondru,et al.  PROLIX: Rapid Mining of Protein-Ligand Interactions in Large Crystal Structure Databases , 2012, J. Chem. Inf. Model..

[6]  Ming-Jing Hwang,et al.  Ligand-binding site prediction using ligand-interacting and binding site-enriched protein triangles , 2012, Bioinform..

[7]  David Ryan Koes,et al.  PocketQuery: protein–protein interaction inhibitor starting points from protein–protein interaction structure , 2012, Nucleic Acids Res..

[8]  Didier Rognan,et al.  Protein-Ligand-Based Pharmacophores: Generation and Utility Assessment in Computational Ligand Profiling , 2012, J. Chem. Inf. Model..

[9]  Didier Rognan,et al.  Structure‐Based Discovery of Allosteric Modulators of Two Related Class B G‐Protein‐Coupled Receptors , 2011, ChemMedChem.

[10]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[11]  H. V. van Vlijmen,et al.  Which Compound to Select in Lead Optimization? Prospectively Validated Proteochemometric Models Guide Preclinical Development , 2011, PloS one.

[12]  Hong Liu,et al.  Computational Screening for Active Compounds Targeting Protein Sequences: Methodology and Experimental Validation , 2011, J. Chem. Inf. Model..

[13]  Didier Rognan,et al.  Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor. , 2011, European journal of pharmacology.

[14]  D. Rognan,et al.  Synthesis, biological evaluation, and automated docking of constrained analogues of the opioid peptide H-Dmt-D-Ala-Phe-Gly-NH₂ using the 4- or 5-methyl substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one scaffold. , 2011, Journal of medicinal chemistry.

[15]  Richard D. Smith,et al.  CSAR Benchmark Exercise of 2010: Combined Evaluation Across All Submitted Scoring Functions , 2011, J. Chem. Inf. Model..

[16]  Didier Rognan,et al.  Enhancing the Accuracy of Chemogenomic Models with a Three-Dimensional Binding Site Kernel , 2011, J. Chem. Inf. Model..

[17]  D. Rognan,et al.  Identification of Nonpeptide Oxytocin Receptor Ligands by Receptor‐Ligand Fingerprint Similarity Search , 2011, Molecular informatics.

[18]  J. Bajorath,et al.  State-of-the-art in ligand-based virtual screening. , 2011, Drug discovery today.

[19]  Didier Rognan,et al.  sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins , 2011, Bioinform..

[20]  Gerard J. P. van Westen,et al.  Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .

[21]  Jürgen Bajorath,et al.  Computational Methodologies for Compound Database Searching that Utilize Experimental Protein–Ligand Interaction Information , 2010, Chemical biology & drug design.

[22]  Maris Lapins,et al.  Towards Proteome–Wide Interaction Models Using the Proteochemometrics Approach , 2010, Molecular informatics.

[23]  Ming-Jing Hwang,et al.  An interaction-motif-based scoring function for protein-ligand docking , 2010, BMC Bioinformatics.

[24]  A. Marchand,et al.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.

[25]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[26]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[27]  Ramaroson Andriantsitohaina,et al.  Estrogen Receptor Alpha as a Key Target of Red Wine Polyphenols Action on the Endothelium , 2010, PloS one.

[28]  Teruki Honma,et al.  Combining Machine Learning and Pharmacophore-Based Interaction Fingerprint for in Silico Screening , 2010, J. Chem. Inf. Model..

[29]  Jürgen Bajorath,et al.  Three‐Dimensional Protein–Ligand Interaction Scaling of Two‐Dimensional Fingerprints , 2009, Chemical biology & drug design.

[30]  Anne Mai Wassermann,et al.  Ligand Prediction for Orphan Targets Using Support Vector Machines and Various Target-Ligand Kernels Is Dominated by Nearest Neighbor Effects , 2009, J. Chem. Inf. Model..

[31]  Didier Rognan,et al.  Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites. , 2009, Journal of medicinal chemistry.

[32]  Obdulia Rabal,et al.  APIF: A New Interaction Fingerprint Based on Atom Pairs and Its Application to Virtual Screening , 2009, J. Chem. Inf. Model..

[33]  Nathanael Weill,et al.  Development and Validation of a Novel Protein-Ligand Fingerprint To Mine Chemogenomic Space: Application to G Protein-Coupled Receptors and Their Ligands , 2009, J. Chem. Inf. Model..

[34]  Tom Blundell,et al.  CREDO: A Protein–Ligand Interaction Database for Drug Discovery , 2009, Chemical biology & drug design.

[35]  Eugen Lounkine,et al.  Similarity Searching Using Fingerprints of Molecular Fragments Involved in Protein-Ligand Interactions , 2008, J. Chem. Inf. Model..

[36]  Jarl E. S. Wikberg,et al.  Interaction Model Based on Local Protein Substructures Generalizes to the Entire Structural Enzyme-Ligand Space , 2008, J. Chem. Inf. Model..

[37]  Jürgen Bajorath,et al.  Ligand-Target Interaction-Based Weighting of Substructures for Virtual Screening , 2008, J. Chem. Inf. Model..

[38]  Jean-Philippe Vert,et al.  Machine Learning for In Silico Virtual Screening and Chemical Genomics: New Strategies , 2008, Combinatorial chemistry & high throughput screening.

[39]  D. Rognan,et al.  Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.

[40]  Jean-Philippe Vert,et al.  Protein-ligand interaction prediction: an improved chemogenomics approach , 2008, Bioinform..

[41]  Chris G. Kruse,et al.  Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. , 2008, Journal of medicinal chemistry.

[42]  Suzanne C Brewerton,et al.  The use of protein-ligand interaction fingerprints in docking. , 2008, Current opinion in drug discovery & development.

[43]  Jean-Philippe Vert,et al.  Virtual screening of GPCRs: An in silico chemogenomics approach , 2008, BMC Bioinformatics.

[44]  D. Rognan.  Chemogenomic approaches to rational drug design , 2007, British journal of pharmacology.

[45]  Gabriele Cruciani,et al.  A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..

[46]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[47]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[48]  Peter Willett,et al.  Knowledge-Based Interaction Fingerprint Scoring: A Simple Method for Improving the Effectiveness of Fast Scoring Functions , 2006, J. Chem. Inf. Model..

[49]  Zhan Deng,et al.  Knowledge-based design of target-focused libraries using protein-ligand interaction constraints. , 2006, Journal of medicinal chemistry.

[50]  David A. Gough,et al.  Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors , 2005, J. Chem. Inf. Model..

[51]  Zhan Deng,et al.  Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening. , 2005, Journal of medicinal chemistry.

[52]  Ricardo L. Mancera,et al.  Expanded Interaction Fingerprint Method for Analyzing Ligand Binding Modes in Docking and Structure-Based Drug Design , 2004, J. Chem. Inf. Model..

[53]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[54]  Z. Deng,et al.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.

[55]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[56]  J. Mason,et al.  New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. , 1999, Journal of medicinal chemistry.